(Q42914097)

English

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

scientific article published on October 1, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Guillaume Charpentier

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Carl Johan Ostgren

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Asa Hellqvist

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ingrid Gause-Nilsson

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

André J. Scheen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20824678

8 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20824678

8 July 2024

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

https://orbi.uliege.be/bitstream/2268/80697/1/Efficacy%20and%20safety%20of%20saxagliptin%20in%20combinationOCR.pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20824678

8 July 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fdmrr.1114

1 reference

10.1002/DMRR.1114

https://api.crossref.org/works/10.1002/DMRR.1114

8 July 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.1114

1 reference

10.1002/DMRR.1114

https://api.crossref.org/works/10.1002/DMRR.1114

8 July 2024

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

540-549

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Earlier triple therapy with pioglitazone in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Use and abuse of HOMA modeling

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of incretin therapy to metformin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.1114

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42914097&oldid=2198829420"